TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01686295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRestore Hair Rejuvenation System
Description: This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham device
Description: This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
Study: NCT03222284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cornerstones4Care Powered by Glooko App
Description: Cornerstones4Care Powered by Glooko App is an iOS or Android smartphone application designed to support diabetes management by offering people with diabetes easily accessible, personalized tools for self-monitoring and education. C4C allows people with diabetes to monitor personal health metrics and blood glucose levels, with the aim to achieve participant behavior changes that may contribute to lower hospitalizations, diabetes-related complications and overall healthcare costs.
Study: NCT04331236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT trains individuals to identify and reframe dysfunctional thoughts to help improve mood and behavior. CBT intervention also includes teaching relaxation and mindfulness strategies, as well as ways to help improve functioning through the use of behavioral goal setting.
Study: NCT02134808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine
Description: Creatine is a nutritional supplement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
Study: NCT04331236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga consists of physical exercises, breathing techniques, and meditation designed to condition the physical body, calm the mind, and stabilize emotions.
Study: NCT03093246

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Description: 3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 100 mg of aspirin daily supplementation over a period of 180 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills over a period of 180 days

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
Study: NCT04157738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid-Acting Insulin
Description: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapid-Acting Insulin
Description: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting insulin
Description: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long acting insulin
Description: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)
Study: NCT00002656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazoloacridine
Description: Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.~Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)
Study: NCT00359398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma sequestration
Description: Venesection of blood (14 ml/kg) and separation to red cells and platelet rich plasma.
Study: NCT03686982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Nitrate Bar
Description: Bar containing Nitrate, L-citrulline; epicatechin; vitamin C and glutathione

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bar
Description: No active ingredients
Study: NCT02867423

Intervention type: DEVICE
Group type: OTHER
Intervention: CK Boost radiation
Description: single dose of 8 Grays is issued by the CK to the 6th week after conventional radiation
Study: NCT02669641

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination Silimarin, Phyllanthus niruri and Choline
Description: Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
Study: NCT00934388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre peritoneal mesh placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Study: NCT03784729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted. For the bilateral BL25, sterile disposable steel needles (Huatuo, Suzhou, China; 0.3 mm×75 mm) will be inserted to a depth of 50-70mm until until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Huatuo, Suzhou, China; 0.3 mm×40 mm) will be inserted to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi. It should be noted that the needle at KI3 will be inserted at an angle of 45°obliquely downward. There will be 18 treatment sessions with 3 times a week for continuous 6 weeks and a 30 min treatment per session.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm .No manipulation of needles without deqi will be conducted. The treatment duration and frequency of sessions for participants in the SA group will be the same as in the acupuncture group.
Study: NCT03161496

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing
Study: NCT01890161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXP1275
Description: AXP1275 50 mg (2 × 25-mg capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AXP1275 matching placebo
Description: AXP1275 matching placebo (2 capsules)
Study: NCT02442115

Intervention type: OTHER
Intervention: Treatment of Functional Constipation by
Description: The NASPGHAN protocol is used by pediatric gastroenterologist to treat functional constipation. Status is monitored at 4 visits and adjustments to treatment are made based on clinical standards and judgment.
Study: NCT02852213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2-hAADC
Description: Initially, subjects will be enrolled sequentially into 2 dose groups. 3 subjects will be enrolled in Cohort 1 and treated with a single dose of AAV2 hAADC (1.3x10 11 vg, delivered as infusate volume of up to 160μL of vector at concentration of 8.3x10 11 vg/mL) on Day 0. Enrollment in Cohort 2 may commence after the last subject in Cohort 1 is treated and followed through Month 3 post-op, with approval of the data safety monitoring board (DSMB). Cohort 2 will receive a higher dose (4.2 x 10\^11 vg, 160 uL). Upon DSMB review of Cohort 1/2 results, Cohort 3 (4-12 yo) and 4 (aged \>/= 13 yo) will be dosed (1.6 x 10\^12 vg, 60uL) in 1-2 sites bilaterally in-between the SNc and VTA. Cohort 5 will follow (aged 24-47 months) at 1.3 x 10\^12 vg, 500uL. Final safety and clinical outcome assessments will be performed 1 year post-surgery. Follow-up analysis will be performed for 2 years post-op. Subjects will be enrolled in a long-term follow-up study to assess safety and clinical status updates.
Study: NCT00272285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: IV, concomitant administration with dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: IV, concomitant administration with dexamethasone
Study: NCT02292667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: The aim of the Transversus Abdominis Plane (TAP) Block is to deposit local anesthetic in the plane between the internal oblique and the transversus abdominis muscles targeting the spinal nerves in this plane. The local anesthetic used in the ETAP study is Ropivacaine 0.375%. 2 ultrasound-guided injections of 10 ml will be performed on each side of the abdominal wall: 1 subcostal injection and 1 supra-iliac injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA with Chlorhydrate of Morphine
Description: Doses of 1 mg of Chlorhydrate of Morphine will be delivered intravenously by the Patient Controlled Analgesia (PCA) pump. The PCA pump is a computerized pump which contains a syringe of 1 mg/ml of Chlorhydrate of Morphine as prescribed by the physician in charge of the patient, and connected directly to a patient's intravenous line. Doses of Chlorhydrate of Morphine can be self-administered by the patient as needed by the having the patient press a button.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA with Chlorhydrate of Morphine
Description: Doses of 1 mg of Chlorhydrate of Morphine will be delivered intravenously by the Patient Controlled Analgesia (PCA) pump. The PCA pump is a computerized pump which contains a syringe of 1 mg/ml of Chlorhydrate of Morphine as prescribed by the physician in charge of the patient, and connected directly to a patient's intravenous line. Doses of Chlorhydrate of Morphine can be self-administered by the patient as needed by the having the patient press a button.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.
Study: NCT01615809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMPHOTERICIN B
Description: The study drug will be administered by inhalation, to hospitalised patients or outpatients in the day hospital.
Study: NCT03536858

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COACH (Communicating about Choices in Transplantation)
Description: COACH is a behavioral communication intervention designed specifically for ESRD patients pursuing kidney transplantation. The COACH program consists of four modules: 1) Kidney transplant options, 2) Discussing your transplant options, 3) Requesting living donation, and 4) Maintaining positive relationships. The content and teaching strategies were guided by the concepts of social cognitive theory as well as principles of adult learning and communication skill acquisition. We believe that patients will transfer these skills to other patients at the hemodialysis clinic who are on their shift.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COACH (Communicating about Choices in Transplantation)
Description: COACH is a behavioral communication intervention designed specifically for ESRD patients pursuing kidney transplantation. The COACH program consists of four modules: 1) Kidney transplant options, 2) Discussing your transplant options, 3) Requesting living donation, and 4) Maintaining positive relationships. The content and teaching strategies were guided by the concepts of social cognitive theory as well as principles of adult learning and communication skill acquisition. We believe that patients will transfer these skills to other patients at the hemodialysis clinic who are on their shift.
Study: NCT02197065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin or placebo will be started at least 4 hours prior to surgery, and continued nightly until postoperative day 45

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02771145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 120947A contact lens disinfecting solution
Description: Investigational 3% hydrogen peroxide solution that uses a platinum catalyst for neutralization and is intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft contact lenses (SCL)
Description: Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (180 days). A fresh pair will be dispensed on Day 0, Day 30, Day 60, and Day 135.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCL preservative solution
Description: Commercially available solution for rinsing soft contact lenses
Study: NCT00968045

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fibrinogen
Description: Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Description: Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
Study: NCT01501500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX
Description: once injection of BTA 3oU into hallux oblique and transverse heads each
Study: NCT04110067

Intervention type: OTHER
Intervention: Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)
Description: Creation of a corneal tissue disk called lenticule and extraction through a minimally invasive incision, utilizing only a femtosecond laser
Study: NCT03889899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study: NCT02389426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TCD baseline
Description: Measurement of cerebral circulation parameters with transcranial doppler baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls.
Study: NCT04297085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biologic sample
Description: Biological samples will be taken from the subjects included
Study: NCT01049399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tideglusib
Description: 800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
Study: NCT01501500

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (0.9% NaCl)
Description: Normal saline 0.3ml to oblique and transverse heads each
Study: NCT02264821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine infiltration
Description: wound infiltration
Study: NCT01049399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tideglusib
Description: 600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: powder for oral suspension administered once daily in fasting conditions for 52 weeks
Study: NCT00883584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMD-1041
Description: Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
Study: NCT03381573

Intervention type: DRUG
Intervention: Roflumilast
Description: Roflumilast
Study: NCT02264821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal morphine
Description: 100 µg added to the spinal anaesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo in spinal anaesthesia and in wound infiltration
Study: NCT03830112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilates exercise with Theraband
Description: The experimental group will perform all the exercises with Theraband® in the same manner than active comparator group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pilates exercise
Description: The active comparator group will perform all the exercises without Theraband®
Study: NCT04417543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride
Description: Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
Study: NCT00775359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 160 mg tablets
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 tablets
Description: Oral tablets
Study: NCT04417543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
Study: NCT02123043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor learning-based training
Description: The motor learning-based training will focus on some of the core concepts in the field of motor learning. The key concepts will include variable practice with respect to speed, feedback (both intrinsic and extrinsic but focusing on extrinsic), feedback focusing on three main variables (wheeling pattern, speed of hand when contacting push rim, push angle), sequential learning (specifically relating to wheeling pattern), and mental imagery (during the rest breaks).
Study: NCT03177798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
Study: NCT02811419

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-scan
Description: examination will be performed with i-scan digital enhancement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard high-definition white light
Description: examination will be performed with high-definition white light
Study: NCT02123043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Practice wheeling
Description: The practice wheeling will consist of the same amount of wheeling exposure compared to the motor learning-based training group, however no feedback regarding an individuals's wheeling will be provided. Participants randomized to this group will wheel for two 5-minute trials/ visit for 6 visits for a total of 60 minutes of wheeling exposure.
Study: NCT02970318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (ACP-196)
Description: Acalabrutinib monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab in combination with idelalisib or bendamustine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idelalisib
Description: Idelalisib in combination with rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine in combination with rituximab